Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics and vaccines to bring more effective gene therapies and personalized medicines to patients.

Explore Our Pipeline

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders

The Latest from Chimeron Bio

In the News

April 12, 2022

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates

Philadelphia, PA and College Station, TX – April 12, 2022 ‒ Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience […]

From Our Blog

July 1, 2020

My Science, My Strongest Tool for Social Justice

The pharma and biotech community can help address not only unmet health needs, but also health inequities. Our role as scientists is critical right now.

Learn more about our COVID-19 Vaccine Program.

See what makes ChaESAR™ a robust anti-viral approach.

Read the Press Release